The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicinVincenzo Quagliariello, Nicola Maurea, Michelino De Laurentiis et al.|Cardiovascular Diabetology|2021Cited by 368
Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugsCarmela Coppola, Nicola Maurea, Anna Di Rienzo et al.|Cancer Treatment Reviews|2017Cited by 80
Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical ModelsVincenzo Quagliariello, Nicola Maurea, Margherita Passariello et al.|Journal of Personalized Medicine|2020Cited by 68
Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to TrastuzumabVincenzo Quagliariello, Nicola Maurea, Margherita Passariello et al.|International Journal of Cardiology|2019Cited by 64
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitorsCarmine Fedele, Claudia De Lorenzo, Gennaro Riccio et al.|Breast Cancer Research and Treatment|2011Cited by 52